Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AXNX vs BSX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BSX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

BSX Overall Winner 6-Pillar Tally: AXNX 0 – 6 BSX Matrix Metrics: AXNX 1 – 9 BSX

As of Nov 20, 2026, Boston Scientific Corp. (BSX) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas BSX carries 60.6/100 (BUY) at $41.98 (13.4x Forward P/E, 19.6% operating margin).

  • Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile BSX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXNX vs BSX
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
BSX NYSE Head-to-Head Winner
Boston Scientific Corp.
Surgical & Medical Instruments & Apparatus
$41.98
-2.35% 1D
Market Cap $62.3B
TTM Revenue $21.1B
Forward P/E 13.4x
Beta / 30D Vol 0.34β · 43% Vol
Unified Composite Score
60.6 / 100 BUY
Tech 58.0 Fund 59.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $43.82 · SMA50: $43.84

6-Pillar Scorecard Institutional Category Breakdown (AXNX 0 – 6 BSX)

Columns: Metric · AXNX · BSX
1. Valuation Multiples BSX
Forward P/E N/M 13.4x
Trailing P/E N/M 18.1x
PEG Ratio N/M 0.73x
EV / Revenue N/M 3.5x
2. Growth & Scale BSX
Revenue Growth (YoY) N/A +1.4%
Earnings Growth (YoY) N/A -21.5%
TTM Revenue (USD) N/A $21.1B
Market Cap N/A $62.3B
3. Profitability & Quality BSX
Gross Margin N/A 68.0%
Operating Margin N/A 19.6%
Net Profit Margin N/A 16.6%
Return on Equity (ROE) N/A 14.1%
4. Balance Sheet & Cash Flow BSX
Cash Generation (TTM) N/A $1.46B
Cash Flow Margin N/A 6.9%
Net Cash / Leverage N/A ROE $11.3B Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BSX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 74.4% (51st %ile)
Put/Call OI Skew N/A 1.42x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BSX
OpEx & R&D Intensity N/A 48.4% of Rev ($10.2B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXNX (1) vs BSX (9)
Institutional Metric AXNX BSX Criterion Row Edge
Market Capitalization
Scale
N/A $62.3B Larger Scale BSX
Trailing P/E Ratio
Valuation
N/M 18.1x Lower Multiple BSX
Forward P/E Ratio
Valuation
N/M 13.4x Lower Multiple BSX
Revenue Growth (YoY)
Growth
N/A +1.4% Higher Growth BSX
Operating Margin (TTM)
Profitability
N/A 19.6% Higher Margin BSX
Net Profit Margin
Profitability
N/A 16.6% Higher Margin BSX
Return on Equity (ROE)
Capital Efficiency
N/A 14.1% Higher ROE BSX
52-Week Range Position
Momentum
50% ($0–$1) 4% ($40–$102) Stronger Trend AXNX
Beta / 30D Volatility
Risk Regime
N/A 0.34β · 43% Vol Lower Realized Risk BSX
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 60.6 / 100 (BUY) Higher Composite BSX
Trailing 12M Revenue (USD)
Operating Scale
N/A $21.1B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 68.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.73x PEG · 3.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $1.46B ($11.3B Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BSX +17.78 pp
AXNX: -26.54% · BSX: -8.76%
3M Horizon AXNX +19.99 pp
AXNX: +16.92% · BSX: -3.07%
6M Horizon AXNX +19.99 pp
AXNX: +16.92% · BSX: -3.07%
1Y Horizon AXNX +19.99 pp
AXNX: +16.92% · BSX: -3.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs BSX. Trailing 12-month operating profitability (AXNX N/A vs BSX 19.6%) and valuation multiples (AXNX N/M vs BSX 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.

AXNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BSX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21.1B
Gross Margin68.0%
Op. Margin19.6%
ROE / Fwd P/E14.1% · 13.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BSX CONSOLIDATION
66d in phase · OBV NEUTRAL
Current IV 74.4%
IV Percentile 51st %ile
Put/Call OI Skew 1.42x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact BSX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $43.69 · IV 38.3%

BSX Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($4,369)

Compare $4,369 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 38.3% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $42.5 / $47.5 Bull Call Spread

Buy 1x $42.5C · Sell 1x $47.5C · 31d

Net Entry $240 Debit
T+5d @ +5% Move +$74 (+31%)
Max Risk / Buffer $240 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $40 / $37.5 Bull Put Spread

Sell 1x $40P · Buy 1x $37.5P · 31d

Net Entry $36 Credit
Max Credit / Yield +$36 (+16.8% RoM)
Max Risk / Buffer -9.3% Cushion ($214 Mgn)
5d Edge & Liquidity 80% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Asymmetric 1x1x1 ($45C + $43/$40P)

+1x 17d $43P · -1x 44d $40P · +1x 31d $45C

Net Entry $147 Debit
T+5d @ +5% Move +$74 (+10.0% RoM)
Max Risk / Buffer -8.4% Put Cushion ($740 Mgn)
5d Edge & Liquidity 2.2x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BSX Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $62.3B market capitalization and 19.6% operating margin.
OpEx & R&D Reinvestment 48.4% of Rev ($10.2B)
90D Engineering Disclosures 0 Published

Investor FAQ AXNX vs BSX Key Questions & Quantitative Answers

As of Nov 20, 2026, Boston Scientific Corp. (BSX) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas BSX carries 60.6/100 (BUY) at $41.98 (13.4x Forward P/E, 19.6% operating margin). Technical & Structure Timing Caution: AXNX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile BSX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BSX leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BSX at +1.4% YoY revenue growth and -21.5% YoY earnings growth on $21.1B TTM revenue (68.0% gross margin, 19.6% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $21.1B for BSX. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus 48.4% of Rev ($10.2B) (0 disclosures) for BSX.

BSX screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BSX trades at 13.4x Forward P/E, 18.1x Trailing P/E, 0.73x PEG, and 3.5x EV/Revenue (6.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus BSX (14.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, BSX carries 74.4% implied volatility (51st %ile, Balanced (25th–60th %ile)), a 1.42x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.34β · 43% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.